期刊文献+

Liguzinediol在不同种属肝微粒体中代谢产物的比较研究 被引量:2

Comparing Metabolites of Liguzinediol in Liver Microsomes among Different Species
下载PDF
导出
摘要 目的比较研究不同种属间liguzinediol的体外代谢产物。方法建立liguzinediol及其体外代谢产物的LC-MS/MS检测方法,采用肝微粒体温孵法研究liguzinediol在大鼠、犬、猴、人等多种属肝微粒体中的代谢产物。结果 liguzinediol在肝脏可发生Ⅰ相和Ⅱ相代谢,并且在大鼠、犬、猴、人肝微粒体温孵体系中均孵育有氧化产物和葡萄糖醛酸结合产物。结论 liguzinediol在大鼠、犬和猴等动物的肝微粒体中的Ⅰ相和Ⅱ相代谢产物与人肝微粒体基本一致,该研究结果可为liguzinediol临床前安全性评价的实验动物选择提供依据。 OBJECTIVE To compare metabolites of liguzinediol in liver microsomes among different species,such as rats,dogs,monkeys and human.METHODS LC-MS/MS method was established to determine liguzinediol and its metabolites.The liver microsome incubation systems among different species were built to research the metabolites of liguzinediol.RESULTS PhaseⅠ and phaseⅡ metabolism of liguzinediol can be occurred in liver.The oxidation and glucuronidase acid binding products were all found in four kinds of liver microsomes.CONCLUSION The metabolites of liguzinediol in liver microsome from rats,dogs and monkeys were consistent with that from human.The results can be used to select laboratory animal for safety evaluation of liguzinediol in preclinical study.
出处 《南京中医药大学学报》 CAS CSCD 北大核心 2016年第1期72-75,共4页 Journal of Nanjing University of Traditional Chinese Medicine
基金 国家自然科学基金(81573304) 高等学校博士学科点专项科研基金(20123237110010) 江苏高校优势学科建设工程资助项目
关键词 代谢产物 LIGUZINEDIOL 肝微粒体温孵 不同种属 metabolites liguzinediol liver microsome incubation different species
  • 相关文献

参考文献7

二级参考文献29

  • 1田振军,李红艳,张志琪,马新庭,郭进.川芎嗪对大鼠心肌细胞膜钙通道的影响及其作用机制[J].体育科学,2006,26(11):80-83. 被引量:8
  • 2YAN C, MILLER CL, ABE J. Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart [J]. Circ Res, 2007, 100(4) : 489-501.
  • 3PEDERSEN SF, O'DONNELL ME, ANDERSON SE, et al. Physiology and pathophysiology of Na^+/H^+ exchange and Na^+-K^+- 2Cl^- cotransport in the heart, brain, and blood[J]. Am J Physiol Regul Integr Comp Physiol, 2006, 291 ( 1 ) : R1-R25.
  • 4QIN J, VALLE G, NANI A, et al. Luminal Ca^2+ regulation of single cardiac ryanodine receptors: insights provided by calsequestrin and its mutants[J]. J Gen Physiol, 2008, 131 (4): 325- 334.
  • 5STAWSKY MT, COLUCCI WS, GOTTIEB SS. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators[J]. Circulation, 2000, 102(18) : 2222-2227.
  • 6COHN JN, ZIESCHE S, SMITH R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFr Ⅲ. Vasodilator-Heart Failure Trial(V-HeFT) Study Group [J]. Circulation, 1997, 96(3): 856-863.
  • 7CLELAND JG, DAUBERT JC, ERDMANN E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure[J]. N Engl J Med, 2005, 352(15) : 1539-1549.
  • 8陆再英,钟南山.内科学[M].北京:人民卫生出版社,2009:493.
  • 9Larissa Lipskaia,Elie R Chemaly,Lahouaria Hadri,etal.Sarcoplasmic reticulum Ca2+ATPase as a therapeutictarget for heart failure[J].Expert Opin Biol Ther,2010,10(1):29.
  • 10刘静.Liguzinedioi先导物的发现及正性肌力活性研究[D].南京中医药大学,2009:14 -15.

共引文献38

同被引文献18

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部